Capitolis Liquid Global Markets LLC Purchases Shares of 878,300 Structure Therapeutics Inc. Sponsored ADR $GPCR

Capitolis Liquid Global Markets LLC purchased a new stake in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 878,300 shares of the company’s stock, valued at approximately $61,086,000. Capitolis Liquid Global Markets LLC owned about 1.24% of Structure Therapeutics at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. State of Wyoming acquired a new stake in Structure Therapeutics in the 2nd quarter valued at about $28,000. EverSource Wealth Advisors LLC lifted its holdings in Structure Therapeutics by 530.0% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the company’s stock valued at $30,000 after acquiring an additional 901 shares during the last quarter. CWM LLC lifted its holdings in Structure Therapeutics by 35.2% in the 4th quarter. CWM LLC now owns 480 shares of the company’s stock valued at $33,000 after acquiring an additional 125 shares during the last quarter. ANTIPODES PARTNERS Ltd lifted its holdings in Structure Therapeutics by 39.1% in the 3rd quarter. ANTIPODES PARTNERS Ltd now owns 4,078 shares of the company’s stock valued at $114,000 after acquiring an additional 1,146 shares during the last quarter. Finally, Police & Firemen s Retirement System of New Jersey acquired a new stake in Structure Therapeutics in the 4th quarter valued at about $127,000. 91.78% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have issued reports on GPCR. HC Wainwright cut their price objective on Structure Therapeutics from $100.00 to $70.00 and set a “buy” rating on the stock in a report on Thursday, June 11th. Wolfe Research began coverage on Structure Therapeutics in a report on Thursday, March 26th. They set a “peer perform” rating on the stock. Citizens Jmp cut their price objective on Structure Therapeutics from $120.00 to $113.00 and set a “market outperform” rating on the stock in a report on Friday, February 27th. Weiss Ratings restated a “sell (d-)” rating on shares of Structure Therapeutics in a report on Tuesday, April 21st. Finally, Canaccord Genuity Group began coverage on Structure Therapeutics in a report on Monday, April 27th. They set a “buy” rating and a $101.00 price objective on the stock. Three investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $106.75.

Structure Therapeutics Trading Up 4.9%

NASDAQ GPCR opened at $45.00 on Thursday. The stock’s 50-day moving average price is $43.09 and its two-hundred day moving average price is $57.53. The company has a market cap of $3.20 billion, a PE ratio of -51.72 and a beta of -1.35. Structure Therapeutics Inc. Sponsored ADR has a 1 year low of $15.80 and a 1 year high of $94.90.

Structure Therapeutics (NASDAQ:GPCR) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.04. Research analysts forecast that Structure Therapeutics Inc. Sponsored ADR will post -1.64 EPS for the current fiscal year.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.